Cargando…

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

PURPOSE: Camrelizumab, an mAb against programmed cell death protein 1 (PD-1), plus nab-paclitaxel exhibited promising antitumor activity in refractory metastatic immunomodulatory triple-negative breast cancer (TNBC). Famitinib is a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Li, Jiang, Yi-Zhou, Wu, Song-Yang, Wu, Jiong, Di, Gen-Hong, Liu, Guang-Yu, Yu, Ke-Da, Fan, Lei, Li, Jun-Jie, Hou, Yi-Feng, Hu, Zhen, Chen, Can-Ming, Huang, Xiao-Yan, Cao, A-Yong, Hu, Xin, Zhao, Shen, Ma, Xiao-Yan, Xu, Ying, Sun, Xiang-Jie, Chai, Wen-Jun, Guo, Xiaomao, Chen, Xizi, Xu, Yanhui, Zhu, Xiao-Yu, Zou, Jian-Jun, Yang, Wen-Tao, Wang, Zhong-Hua, Shao, Zhi-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Clinical Trials: Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365373/ https://www.ncbi.nlm.nih.gov/pubmed/35247906 http://dx.doi.org/10.1158/1078-0432.CCR-21-4313

Ejemplares similares

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
por: Qu, Yuan-Yuan, et al.
Publicado: (2022)

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
por: Xia, Lingfang, et al.
Publicado: (2022)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
por: Ding, Xi, et al.
Publicado: (2023)

Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma
por: Yang, Shuwen, et al.
Publicado: (2022)

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
por: Xia, Lingfang, et al.
Publicado: (2022)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion
por: Lin, Ju-Li, et al.
Publicado: (2022)

Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases
por: Zhang, Chong, et al.
Publicado: (2023)

Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study
por: Yin, Chen, et al.
Publicado: (2023)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
por: Lin, Zhenyu, et al.
Publicado: (2021)

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
por: Wu, Song-Yang, et al.
Publicado: (2022)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
por: Wang, Ya-Qin, et al.
Publicado: (2020)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers
por: Yu, Yi, et al.
Publicado: (2021)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III
por: Jiang, Minlin, et al.
Publicado: (2021)

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
por: Xu, Rui-Hua, et al.
Publicado: (2017)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
por: Liu, Qiu-Ping, et al.
Publicado: (2023)

Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020)

Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
por: Ge, Sai, et al.
Publicado: (2016)

Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
por: Zhou, Yi-Fan, et al.
Publicado: (2021)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
por: Yang, Lei, et al.
Publicado: (2022)

Identification of key immune cell-related genes involved in tumorigenesis and prognosis of cervical squamous cell carcinoma
por: Yan, Chunxiao, et al.
Publicado: (2023)

Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)
por: Yang, Yang, et al.
Publicado: (2022)

Successful response to camrelizumab in metastatic bladder cancer: A case report
por: Xie, Chen, et al.
Publicado: (2022)

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
por: Deng, Jia-Yi, et al.
Publicado: (2023)

Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer
por: Peng, Xiao-Xiao, et al.
Publicado: (2020)

Identification of an HLA-A*0201–restricted CD8(+) T-cell epitope SSp-1 of SARS-CoV spike protein
por: Wang, Baomei, et al.
Publicado: (2004)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2p5u8hkbtvkhdt0s2mmq6mjorq